Frequency of Genitourinary Complications After Radiation for Localized Prostate Cancer
Overview
This population-based prospective cohort study evaluated the cumulative incidence of genitourinary toxicity (GUT) following external beam radiotherapy (EBRT) for localized prostate cancer. It identified clinical predictors of GUT and quantified the burden of hospital admissions and procedures related to treatment complications.
Background
Prostate cancer is the second most common cancer in men worldwide, with most patients presenting with localized disease amenable to curative treatment. Radiotherapy is a common treatment modality, but late genitourinary toxicity remains poorly characterized outside specialized centers. Understanding the incidence and burden of GUT after radiotherapy is essential for informed patient counseling and management.
Data Highlights
The study included patients treated with EBRT between 1998 and 2019 in South Australia, excluding metastatic cases and those receiving adjuvant radiotherapy post-prostatectomy. Patient data were linked from the SA-PCCOC registry and hospital administrative databases to identify GUT-related admissions and procedures. Baseline characteristics, treatment details, and clinical outcomes were analyzed using cumulative incidence and Cox regression models.
Key Findings
The cumulative incidence of hospital admission for treatment-related genitourinary toxicity was determined at a population level over a median follow-up period.
Clinical factors such as age, comorbidity index, anticoagulant use, T stage, baseline PSA, and radiation dose were evaluated for their association with GUT risk.
Patients treated with advanced radiotherapy techniques (IMRT/VMAT post-2009) were compared to those treated with 3DCRT to assess differences in toxicity incidence.
The burden of treatment was quantified by the volume of hospital admissions and categorized procedures: non-operative (catheterization, irrigation), minor operative (urethral dilation, cystoscopy), and major operative (transurethral resection, ureteroscopy, open surgery).
Multidisciplinary expert consensus guided the selection of ICD-10 and ACHI codes to accurately capture GUT-related hospital events.
Clinical Implications
Clinicians should be aware of the risk and timing of late genitourinary toxicity following EBRT for localized prostate cancer, especially in patients with identified risk factors. Monitoring and early intervention may reduce the burden of hospital admissions and invasive procedures. The findings support the need for patient-centered discussions regarding long-term treatment sequelae when considering radiotherapy options.
Conclusion
This large population-based study provides valuable insights into the incidence and clinical predictors of genitourinary toxicity after prostate radiotherapy, highlighting the significant healthcare burden associated with these complications. Enhanced understanding of these risks can improve patient counseling and management strategies.
References
Prostate Cancer Statistics and Treatment Options [1-4]
Challenges in Recording Late Radiotherapy Toxicity [5-7]
Single-Center vs Multi-Institutional Studies on GUT [7-14]
STROBE Statement for Observational Studies Reporting [15]
Recent research at Roswell Park Comprehensive Cancer Center led by Anurag Singh, MD, Director of Radiation Research, has shown that for patients with peripherally located lung cancer, one treatment of stereotactic body radiation therapy (SBRT) is equally effective as longer courses radiation therapy.
